STOCK TITAN
  1. Home
  2. News
  3. BCTX

Briacell Therapeutics Corp. Common Shares - BCTX STOCK NEWS

Welcome to our dedicated page for Briacell Therapeutics Common Shares news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics Common Shares stock.

BriaCell Therapeutics Corp (NASDAQ: BCTX) is a pioneering biotechnology company headquartered in Los Angeles, specializing in the development of immunotherapy treatments for cancer management. The company’s innovative approach focuses on harnessing the body's immune system to target and eliminate cancer cells, providing new hope for patients battling this devastating disease.

Central to BriaCell's portfolio is the BriaVax vaccine, which has shown promising results in early-phase clinical trials. In two compelling FDA Phase I studies involving late-stage breast cancer patients, BriaVax demonstrated unique and unprecedented outcomes, showcasing its potential as a groundbreaking treatment. Building on these successes, BriaCell is aggressively advancing towards a Phase I/II clinical trial, aiming to expand its vaccine's application to a larger cohort of breast cancer patients.

In addition to BriaVax, the company is also developing Bria-IMT, currently in a Phase I/IIa clinical trial targeting metastatic breast cancer. Bria-IMT represents a targeted and safe approach to treating advanced-stage breast cancer, reinforcing BriaCell's commitment to innovative cancer therapies. Another significant development in their pipeline is the Bria-OTS ('off-the-shelf') personalized immunotherapy, designed to match the patient's HLA type, further customizing and enhancing the treatment's effectiveness.

While BriaCell's current focus remains on breast cancer, the company is exploring the potential of applying its vaccine technology to other cancer types, broadening its impact in the oncology field. With a strategic vision and robust pipeline, BriaCell is poised to make significant contributions to cancer treatment and patient care.

For more detailed updates and the latest news about BriaCell Therapeutics Corp, visit their website or contact them directly. The company remains committed to transparency and regularly shares progress on their groundbreaking research and clinical trials.

News

BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic

Rhea-AI Summary
BriaCell to host virtual KOL event on Bria-IMT™ potential in advanced metastatic breast cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
conferences
-
News

BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast Cancer

Rhea-AI Summary
BriaCell partners with NYCBS to evaluate Bria-IMT combination in Phase 3 study for advanced breast cancer patients in New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
partnership clinical trial
-
News

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer

Rhea-AI Summary
BriaCell's pivotal Phase 3 study of Bria-IMT™ in combination with an immune checkpoint inhibitor has been fully approved and will enroll patients with advanced metastatic breast cancer. Positive results could lead to full approval and marketing authorization for Bria-IMT™. The study's primary endpoint is overall survival. Bria-IMT™ is currently under Fast Track Designation by the FDA. Successful completion of the study would allow BriaCell to submit a Biologics License Application.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
clinical trial
News

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

Rhea-AI Summary
BriaCell reports strong patient survival benefit in advanced metastatic breast cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
none
-
News

BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

Rhea-AI Summary
BriaCell closes arrangement, spinning out pipeline assets to BriaPro Therapeutics Corp. BriaCell shareholders receive one common share of SpinCo for each BriaCell share held, and new common shares of BriaCell. BriaCell retains 66.6% of SpinCo common shares. BriaCell common shares to begin trading on September 5, 2023. Refer to proxy statement for more details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
-
News

BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast Cancer

Rhea-AI Summary
BriaCell announces plans for Phase 2 clinical study of Bria-IMT™ in combination with a check point inhibitor in TNBC patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
clinical trial
News

BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing Shareholders

Rhea-AI Summary
BriaCell receives court approval for plan of arrangement to spin-out pipeline assets to BriaPro Therapeutics Corp.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
-
News

BriaCell Therapeutics Corp. Announces Voting Results From Special Meeting

Rhea-AI Summary
Shareholders approved spinout of BriaPro Therapeutics including pipeline assets for cancer treatment. Share reorganization expected by August 31, 2023. Closing subject to court and regulatory approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
News

BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS™ Immunotherapy for Cancer

Rhea-AI Summary
BriaCell Therapeutics Corp. has been awarded a research grant by the National Cancer Institute (NCI) to advance its platform of personalized off-the-shelf immunotherapies for cancer. The non-dilutive grant will be used for the development of Bria-OTS™ for advanced metastatic breast cancer, prostate cancer, lung cancer, and melanoma. The company's approach has shown promising top-line survival and quality of life outcomes in patients. The NCI award validates their approach and may lead to future non-dilutive funding opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
News

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

Rhea-AI Summary
IPA (IMMUNOPRECISE ANTIBODIES LTD.) reported a 6.7% increase in revenue for the fiscal year 2023, reaching $20.7 million. Adjusted for currency effects, the growth was 9.0%. The company also achieved its highest quarterly revenue total of $5.6 million. IPA's CEO, Dr. Jennifer Bath, expressed optimism for the future, highlighting the potential of their in silico suite of services and data management capabilities to drive growth in the coming year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
earnings

FAQ

What is the current stock price of Briacell Therapeutics Common Shares (BCTX)?

The current stock price of Briacell Therapeutics Common Shares (BCTX) is $0.561 as of December 20, 2024.

What is the market cap of Briacell Therapeutics Common Shares (BCTX)?

The market cap of Briacell Therapeutics Common Shares (BCTX) is approximately 26.5M.

What does BriaCell Therapeutics Corp do?

BriaCell Therapeutics Corp specializes in developing immunotherapy treatments for cancer, focusing primarily on breast cancer.

What are the main products of BriaCell Therapeutics Corp?

BriaCell's main products include the BriaVax vaccine, Bria-IMT, and Bria-OTS, which are all designed to treat advanced-stage breast cancer.

What is BriaVax?

BriaVax is a patented vaccine developed by BriaCell for treating late-stage breast cancer, showing promising results in early clinical trials.

What clinical trials is BriaCell currently conducting?

BriaCell is conducting a Phase I/IIa clinical trial for Bria-IMT in metastatic breast cancer and is planning to launch a Phase I/II trial for BriaVax.

Where is BriaCell Therapeutics Corp headquartered?

BriaCell Therapeutics Corp is headquartered in Los Angeles, California.

Is BriaCell focusing only on breast cancer?

Currently, BriaCell's primary focus is on breast cancer, but the company is exploring the potential to apply its vaccine technology to other cancer types.

How can I contact BriaCell Therapeutics Corp?

You can contact BriaCell through their website or by reaching out to their President & CEO, Dr. William V. Williams, at 1-888-485-6340 or info@briacell.com.

What makes BriaCell's immunotherapy approach unique?

BriaCell's approach leverages the body's immune system to target cancer cells, with products like Bria-OTS offering personalized treatment by matching the patient's HLA type.

Who are the primary contacts for media and investor relations at BriaCell?

For media relations, contact Jules Abraham at CORE IR; for investor relations, contact CORE IR at investors@briacell.com.

Where can I find the latest news about BriaCell Therapeutics Corp?

The latest news about BriaCell can be found on their website and through regular updates provided via their press releases and news announcements.

Stock BCTX logo
Briacell Therapeutics Corp. Common Shares

Nasdaq:BCTX

BCTX Rankings

#5185 Ranked by Market Cap
N/A Ranked by Dividends

BCTX Stock Data

26.52M
29.85M
19.6%
5.68%
1.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WEST VANCOUVER